横浜市立大学泌尿器科およびその関連施設を加えた13施設で, TFLXを使用して有効性と安全性について検討した.1)女子急性単純性膀胱炎164例の総合有効率は98.78%であった.2)男子急性単純性膀胱炎4例, 急性単純性腎盂腎炎3例, 非淋菌性尿道炎1例, 複雑性尿路感染症7例にも投与して100%の有効率がえられた.3)原因菌の中で, グラム陰性菌は100%の消失率で, グラム陽性菌は90.60%の消失率であった.4)副作用発現は5例にみられ, その発現率は2.42%であったWe clinically evaluated the usefulness of a new oral antimicrobial agent, TFLX, in the field of urology. The dose administered was 150 mg t.i.d and the duration of administration was 3 days. The clinical effect was evaluated according to the criteria of the Japanese UTI committee. The clinical response obtained on 164 female patients with acute simple cystitis was excellent in 118, moderate in 44 and poor in 2 patients. The efficacy rate was 98.78%. The clinical response obtained on 4 male patients with acute simple cystitis was excellent in 2 and moderate in 2 patients. The efficacy rate was 100%. The clinical response obtained on 3 female patients with simple pyelonephritis was excellent in 2 and moderate in 1 patient. The efficacy rate was 100%. The clinical response obtained on one patient with non-gonococcal urethritis was excellent by doctor's evaluation. The clinical response obtained on 7 patients with complicated UTI was excellent in 3 and moderate in 4 patients. The efficacy rate was 100%. Three patients complained of stomach distress or malaise and 2 patients developed rash. No abnormal laboratory data were observed. Thus, TFLX appears to be safe and suitable for use in the field of urology
